AI and home monitoring could help diabetes patients see their risks clearly

NCT ID NCT06607497

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether an AI tool that shows patients how their blood sugar control compares to others, combined with home monitoring, can improve risk perception and blood sugar levels in adults with poorly controlled type 2 diabetes. About 360 participants aged 36–65 will be split into three groups: one gets the AI tool plus home monitoring, one gets only the AI tool, and one gets usual care. The goal is to see if these tools help people better understand their risks and take action to improve their health.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
AI-enabled risk communication tool (PERDICT.AI) and telemonitoring system (PTEC-DM)
What this could lead to
If successful, this approach could help people with type 2 diabetes better understand their personal risks and improve blood sugar control, potentially reducing complications.
What could go wrong
This is a relatively small, early-stage trial focused on behavior and perception, not a direct treatment. The improvements may be modest or not sustained, and results may not apply to all diabetes patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • SingHealth Polyclinics

    Singapore, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.